In the transplant surgery, reactive oxygen species (ROS) from the reperfused tissue cause ischemia-reperfusion injury, resulting in the primary graft failure. We have recently reported that Rho-kinase, an effecter of the small GTPase Rho, plays an important role in the ROS production in the hyperacute phase of reperfusion; however, the sources and mechanisms of the ROS production remain to be elucidated. The aim of this study was to investigate the source of ROS production with a special reference to Rho-kinase to develop a new strategy against ischemia-reperfusion injury. In an in vivo rat model of liver transplantation, Kupffer cells in the graft were depleted using liposome-encapsulated dichloromethylene diphosphonate to examine the source of ROS production. The effect of adenoviral-mediated overexpression of a dominant-negative Rho-kinase (AdDNRhoK) in hepatocytes in the graft was also examined. Kupffer cells were not involved in the ROS production, whereas the AdDNRhoK transfection to hepatocytes significantly suppressed the ROS production. Furthermore, the ROS production was dose-dependently inhibited by apocynin, an NADPH oxidase inhibitor. Expression of DNRhoK also suppressed the release of pro-inflammatory cytokines, and ameliorated the lethal liver injury with a significant prolongation of the survival. These results suggest that the Rho-kinase-mediated pathway plays a crucial role in the ROS production through NADPH oxidase in hepatocytes during the hyperacute phase of reperfusion in vivo. Thus, Rhokinase in hepatocytes may be a new therapeutic target for the prevention of primary graft failure in liver transplantation.
Introduction
Liver transplantation is an effective therapy for irreversible liver diseases. Recent advances in organ preservation and immunosuppression have improved outcomes of liver transplantation. However, 20% of liver transplants still fail from various complications within 1 year. 1 One apparent cause of the transplant failure is primary graft non-function, 1 which occurs as a combined result of ischemia-reperfusion (I/R) injury and secondary-tissue regeneration impairment due to size mismatch. 1 Previous studies have indicated that the extent of I/R injury may in part determine the likelihood of subsequent acute and chronic graft rejection. 2, 3 To improve the transplantation therapy as a safer procedure, it is important to overcome this I/R injury.
Since tissue injury is caused in part by reactive oxygen species (ROS), including superoxide anion, at the time of I/R injury, 4 ,5 the involvement of ROS in the pathogenesis of graft failure has also been reported. 6, 7 However, the sources of and mechanisms for the ROS production are still controversial. According to many theories, in liver transplantation, the source of ROS after reperfusion is resident macrophages, that is Kupffer cells. [8] [9] [10] However, recent studies have shown that the ROS production after reperfusion consists of two phases, 11 the hyperacute phase and the late phase, and have suggested that the ROS in the hyperacute phase are derived from hepatocytes. 11, 12 It has also been reported that when intracellular production of ROS is inhibited by transfecting hepatocytes with mitochondrial superoxide dismutaseencoding adenovirus vectors, the post-I/R activity of nuclear factor-kb (NF-kb) and activator protein-1 (AP-1), the so-called redox signaling pathway is inhibited. 13 This study indicated that ROS generated after I/R are involved in intracellular signal transduction, and suggested the possible usefulness of gene therapy targeting the sources of ROS production. 13 In view of these findings, we consider that the ROS production in the hyperacute phase of reperfusion is an important initial signaling to accelerate inflammation in a chain reaction, and could be a new therapeutic target for the prevention of primary graft non-function in liver transplantation.
The intracellular enzymatic sources responsible for the I/R-induced production of ROS in hepatocytes have also not been fully elucidated. Only some in vivo and in vitro studies have shown that xanthine oxidase, 14 mitochondrial electron transport chain, 15 cycloxygenase 16 and NADPH oxidase 11 are important sources of ROS produced during reperfusion.
Previous in vitro and in vivo studies suggested that small G-protein Rho and its effector Rho-kinase play an important role in various cellular functions. 17 We have demonstrated that Rho-kinase is substantially involved in the pathogenesis of cardiovascular diseases in both animals and humans. [18] [19] [20] [21] Rho-kinase is also known to regulate the mechanism of ROS production. 17, 22, 23 Indeed, we have also recently demonstrated that Rhokinase is involved in the ROS production in the hyperacute phase of the reperfusion and pro-inflammatory cytokine production in hepatic I/R injury in rats in vivo. 24 Furthermore, previous reports including ours 25, 26 show that Rho-kinase can regulate NF-kb activation through IkB phosphorylation in inflammatory responses. However, it is unknown whether Rho-kinase is directly involved in the intracellular signal transduction to produce ROS in vivo in the hyperacute phase of reperfusion.
In the present study, we thus aimed to elucidate the source of ROS production in reperfused liver tissue and to examine the possible importance of Rho-kinase in the ROS production in the hyperacute phase of I/R injury of the liver. For this purpose, we employed adenovirusmediated in vivo gene transfer of dominant-negative Rho-kinase. 11, 13, 17 Results
Source of ROS in hyperacute phase after reperfusion
To investigate the involvement of Kupffer cells in the ROS production after reperfusion, we eliminated Kupffer cells from grafts by the prior administration of liposomeencapsulated C1 2 MDP. The depletion of Kupffer cells from grafts was confirmed by immunohistochemistry with anti-macrophage antibody, ED-1 ( Figure 1A ). Despite the Kupffer-cell depletion, ROS production was not inhibited in the 15-30 min period after reperfusion ( Figure 1B-a) . However, in the 30-45 min period after reperfusion, significant inhibition of ROS production was observed in the C1 2 MDP-treated group ( Figure 1B-b) . These results suggest that the source of ROS in the hyperacute phase of reperfusion is hepatocytes.
LacZ expression and inhibitory effect on Rho-kinase activity by AdDNRhoK in the liver
To inhibit efficiently Rho-kinase-dependent mechanisms of ROS production in rat hepatocytes, we used a recombinant replication-deficient adenovirus encoding the dominant-negative form of Rho-kinase, AdDNRhoK. The adenovirus vectors with b-galactosidase (AdLacZ) was used as a control. Three days after the injection of virus vectors, the expression of LacZ protein was noted (B) Effect of Kupffer cell depletion on ROS production in the hyperacute phase of reperfusion. ROS production was assessed by lucigenin chemiluminescence (a) 15-30 min period (n ¼ 6) and (b) 30-45 min period (n ¼ 6) after reperfusion. Despite the Kupffer cell depletion, ROS production was not inhibited in the 15-30 min period. However, in the 30-45 min period, significant inhibition of ROS production was observed in the C1 2 MDP-treated group. After addition of 20 mmol/l tiron, a superoxide-specific scavenger, ROS counts were acutely normalized in each group (n ¼ 6 each). Results are expressed as the mean7s.e.m. **Po0.01. Cl 2 MDP, dichloromethylene diphosphonate; ROS, reactive oxygen species.
Rho-kinase in treatment of cold I/R-induced acute lethal liver injury S Shiotani et al on cytoplasm of hepatocytes ( Figure 2A ). X-gal staining showed 470% transduction rate in livers at 6 Â 10 9 pfu AdLacZ (Figures 2A-e, f) , but only o10% at 1 Â 10 9 pfu AdLacZ (Figures 2A-c, d ).
Western blot analysis showed that the extent of ERM (ezrin, radixin, moesin) phosphorylation, a marker of Rho-kinase activity, in the liver was enhanced in the AdLacZ control group, and was significantly suppressed in the AdDNRhoK group ( Figure 2B ).
Effect of DNRhoK expression and inhibitors on ROS production in hyperacute phase of reperfusion I/R caused an early burst and a late peak of superoxide generation. 11 In our model of rat transplantation, the early burst of superoxide production was noted 15-30 min after reperfusion (data not shown). To examine whether Rho-kinase is involved in the ROS production in the hyperacute phase of reperfusion, we measured ROS production 15-30 min after reperfusion using the lucigenin chemiluminescence method (Figure 3 ). The production of ROS in the sham group averaged 26.071.2 counts/10 min/mg dry weight of liver tissue, and the ROS production increased by ninefold in liver tissues in the AdLacZ control group (241.6725.2 counts/ 10 min/mg, Po0.01 vs sham group). In contrast, the ROS production was significantly inhibited in the AdDNRhoK group (6 Â 10 9 pfu; 128.9727.8 counts/ 10 min/mg, Po0.01 vs control group with AdLacZ). At the dose of 1 Â 10 9 pfu AdLacZ, with only o10% transduction rate, no significant inhibition was noted (203.6710.5 counts/10 min/mg). Furthermore, we used tiron (4,5 dihydroxy-1,3-benzenedisulfonic acid disodium salt), a superoxide-specific scavenger, in all experiments to confirm the validity of the use of licigenin for the measurement of superoxide production. The increased ROS production in each group was acutely normalized in the presence of 20 mmol/l tiron ( Figure 3) .
To narrow down the mechanism of the ROS production in the hyperacute phase, we inhibited a typical mechanism of ROS production in the liver using inhibitors, including COX inhibitor (indomethacin; 100 mM), mitochondrial transport chain inhibitor (rotenone; 5 mM) and NADPH oxidase inhibitor (apocynin100, 200 mM) (Figure 3 ). The ROS production was examined with lucigenin chemiluminescence method and all the inhibitors were added to liver tissue immediately before measurement. 23 The ROS production was decreased , the 1 Â 10 9 pfu AdLacZ-infected (c and d) and 6 Â 10 9 pfu AdLacZ-infected (e and f) rats. The virus used in these studies expressed LacZ protein on cytoplasm of hepatocytes. >70% transduction rate was observed in livers infected with 6 Â 10 9 pfu AdLacZ. (B) Quantified analysis of the western blotting for Rho-kinase-dependent phosphorylations of ERM (ezrin, radixin, moesin) family, a marker of Rho-kinase activity, in the liver from the 6 Â 10 9 pfu AdLacZ and AdDNRhoK-infected rats at 15 min after reperfusion (n ¼ 5 each). The phosphorylations of those target proteins of Rho-kinase were significantly suppressed in the AdDNRhoK group. *Po0.05. AdDNRhoK, adenoviral-mediated overexpression of a dominant-negative Rho-kinase; AdLacZ, adenovirus vectors with b-galactosidase.
Rho-kinase in treatment of cold I/R-induced acute lethal liver injury S Shiotani et al dose-dependently only when apocynin was added ( Figure 3 ). These results suggest that ROS derived from hepatocyte in the hyperacute phase of reperfusion is produced through the NADPH oxidase system.
Inhibition of Rho-kinase leads to suppression of ischemia/reperfusion-induced pro-inflammatory cytokine production and acute liver necrosis Three hours after reperfusion, the pro-inflammatory cytokines (TNF-a, IL-1b) concentrations in the liver were significantly increased in the AdLacZ control group and were significantly suppressed in the AdDNRhoK group ( Figure 4A ).
Serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT), markers of hepatocellular injury, were measured 12 h after I/R ( Figure 4B ). The transfection of DNRhoK significantly suppressed the serum concentrations of both AST and ALT. Histological analysis demonstrated that ischemia followed by 12 h of reperfusion caused lethal necrosis in AdLacZ control group, which was markedly reduced in the AdDNRhoK group ( Figures 4C-a, b) .
Survival of animals and evaluation of microcirculatory disturbance
Seven-day survival after the liver transplantation was significantly better in the AdDNRhoK group compared with the AdLacZ control group (Figure 5a ). All nonsurvivors in the AdLacZ control group died within 2 days after reperfusion and showed massive ascites at the time of death, suggesting that the cause of death after reperfusion was due to primary graft non-function. In contrast, four of the five survivors in the AdDNRhoK group survived indefinitely. Furthermore, to support these findings, we investigated the microcirculatory disturbance, which shows the end stage of I/R injury and shows one of the results of primary graft nonfunction, using LDPI analyzer (Figure 5b ). However, no significant inhibition was noted immediately after reperfusion, 30 min and 3 h after reperfusion. However, 12 h after reperfusion, the microcirculatory disturbance was noted in the control group with AdLacZ, which was significantly suppressed in the AdDNRhoK group (Figure 5b ).
Discussion
The novel findings of the present study were that (1) Kupffer cells are not the source of ROS in the hyperacute phase of reperfusion, (2) Rho-kinase mediates ROS production in the hyperacute phase through the NADPH oxidase system in hepatocyte and (3) Rho-kinase in Figure 3 Inhibition of ischemia/reperfusion-induced ROS production in rat liver by expression of DNRhoK and inhibitors in the hyperacute phase of reperfusion (n ¼ 4-6 each). ROS production was significantly suppressed in the 6 Â 10 9 pfu AdDNRhoK group and the apocynine (NADPH oxidase inhibitor)-treated group dosedependently, but not suppressed by indomethacine (non-specific COX inhibitor) and rotenone (mitochondria complex I inhibitor). These results suggested the crucial role of Rho-kinase-regulated ROS production through NADPH oxidase system in hepatocytes during the hyperacute phase of reperfusion in vivo. Results are expressed as the mean7s.e.m. **Po0.01. AdDNRhoK, adenoviralmediated overexpression of a dominant-negative Rho-kinase; AdLacZ, adenovirus vectors with b-galactosidase; COX, cycloxygenase; DNRhoK, dominant-negative Rho-kinase; ROS, reactive oxygen species. after cold ischemia for 24 h followed by 12 h of reperfusion. Liver section from the control group showed lethal necrosis and severe sinusoidal congestion (a), whereas these findings were completely suppressed in AdDNRhoK group (b). Results are expressed as the mean7s.e.m. **Po0.01. AdDNRhoK, adenoviral-mediated overexpression of a dominant-negative Rho-kinase; AdLacZ, adenovirus vectors with b-galactosidase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DNRhoK, dominant-negative Rhokinase; IL-1b, interleukin-1b; I/R, ischemia/reperfusion; TNF-a, tumor necrosis factor-a.
Rho-kinase in treatment of cold I/R-induced acute lethal liver injury S Shiotani et al hepatocyte can be an important therapeutic target for the treatment of I/R injury. Thus, the present study provides the first in vivo evidence for the role of Rho-kinasedependent ROS production in hepatic I/R injury, demonstrating that Rho-kinase in hepatocyte is a new therapeutic target for prevention of primary graft nonfunction in liver transplantation.
Source of ROS production in hyperacute phase of reperfusion
In this study, we showed that immediately after reperfusion ROS were not derived from Kupffer cells in vivo, using the C1 2 MDP method with Kupffer-cell depletion. These data support the scant data available to date. 27 The various studies have investigated the involvement of Kupffer cells in the ROS production. [8] [9] [10] However, the majority of these studies employed an ex vivo perfusion system, [8] [9] [10] and only a few studies used an in vivo model in which blood factors flow from the recipient. 5, 7, 11 Moreover, the Kupffer cell-depleting effect of gadolinium chloride is currently considered insufficient. In this study, we overcame these problems, and observed Kupffer cell-independent ROS production at 15-30 min period after reperfusion, and Kupffer celldependent ROS production at 30-45 min period after reperfusion.
Involvement of Rho-kinase in the mechanism of ROS production in hyperacute phase of reperfusion
In the present study, Rho-kinase was activated at the protein level as early as 15 min after reperfusion in the AdLacZ control group in comparison with the sham group, and it was inhibited by pre-transfection to donor hepatocytes with AdDNRhoK. These findings indicate the existence of a mechanism by which the Rhokinase-mediated intracellular signaling pathway is upregulated in hepatocytes in the hyperacute phase after reperfusion or during preservation. In this study, we were also able to demonstrate, by introducing AdDNRhoK into hepatocytes, that Rho-kinase is directly involved in the intracellular signal transduction to produce ROS in hepatocytes in vivo in the hyperacute phase of reperfusion.
Previous studies demonstrated that xanthine oxidase and the mitochondrial electron transport chain are the main intracellular sources of ROS in reperfused liver. 14, 15 This is particularly true for xanthine oxidase, as exemplified by studies demonstrating that I/R injury can occur in organs known to be deficient for this enzyme, 28 and especially in liver tissue, there are no changes in xanthine oxidase activity before and after reperfusion injury. 29, 30 Those studies questioned the role of the enzyme in reperfusion injury. 31 In the present study, ROS production in the hyperacute phase was inhibited by an NADPH oxidase inhibitor, suggesting that Rho-kinase is closely related to the NADPH oxidase system in hepatocytes. The NADPH oxidase has been known only in phagocytes; however, in recent years, the NADPH oxidase homolog Nox in non-phagocytes has been cloned. 32 Recently, we reported that Rho-kinase associates with this Nox, and is involved in NADPH oxidase-mediated ROS production in vascular endothelial cells. 23 Another report also 
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showed that the Rho-binding protein Rac1, with which Rho/Rho-kinase pathway interacts, regulates the membrane NADPH oxidase that produces ROS during mouse liver I/R. 11 Studies on Rho-kinase and the mechanism for ROS production in the liver have just begun. In this study, we were able to show the possibility that Rhokinase is involved in the NADPH oxidase-mediated production of ROS in hepatocytes. The relationships between Nox expression and Rho-kinase in hepatocytes remain to be examined in future studies.
Involvement of Rho-kinase in cold ischemia/ reperfusion-induced cytokine production
In this study, we showed that the ROS production at 15 min after reperfusion could be regulated by Rhokinase. In addition, with the transfection of DNRhoK, we were able to suppress the production of pro-inflammatory cytokines (TNF-a, IL-1b) in liver tissue after 3 h of reperfusion. These results suggest that ROS in the hyperacute phase of reperfusion are required for the production of TNF-a and IL-1b and the gene therapy using AdDNRhoK can block the redox-sensitive signaling pathway, such as NF-kb, AP-1, which regulate ROS production in the hyperacute phase of reperfusion in the liver. The transcription of the cytokine is controlled in part by NF-kb, 33 and NF-kb activation is sensitive to ROS in I/R in vivo. 13 Recent experiments in rat and mouse models of I/R-induced hepatic injury have shown that NF-kb binding markedly increases after 30-60 min of reperfusion and diminishes after 4-5 h of reperfusion. 34 On the basis of these findings, we consider that ROS production, which is regulated by Rho-kinase 15 min after reperfusion, resulted in the cytokine production through the activation of NF-kb in liver tissue. Recently, it was also shown that NF-kb activation is directly regulated by the Rho/Rho-kinase pathway. 25, 26 Thus, in this study, constitutive inhibition of NF-kb by DNRhoK might have inhibited the production of pro-inflammatory cytokines and time-dependent inflammatory response after reperfusion.
Inhibition of Rho-kinase in cold ischemia/reperfusioninduced acute lethal liver injury
In this study, despite the incomplete inhibition of ROS production by AdDNRhoK in hyperacute phase of reperfusion, the lethal liver injury 12 h after reperfusion was completely inhibited and the microcirculation of the liver was kept satisfactory. This suggests that it is important to inhibit the early burst of ROS production to protect the grafts against I/R injury, and also suggested that Rho-kinase activation results in other consequences, such as the expression of adhesion molecules or heat shock proteins, and inflammatory cell migration of I/R and the primary graft non-function. These mechanisms require further study in vivo.
Limitation of this study
Several limitations should be mentioned for the present study. First, we did not examine the effect of AdDNRhoK transfection on hepatic stellate cells (HSCs) and sinusoidal endothelial cells (SECs). The contractility of HSCs is partially regulated by vasorelaxing agents, such as nitric oxide (NO). The previous report demonstrated that Rhokinase negatively regulated the production of NO by endothelial nitric oxide synthase (eNOS) in hepatic SECs, which play an important role in hepatic microcirculation. 35 However, in this study, there was no change in the hepatic microcirculation at 0 min, 30 min and 3 h after reperfusion between the AdLacZ and the AdDNRhoK group with an LDPI analyzer (Figure 5b ). These data support our result that AdDNRhoK only infected hepatocytes and it did not influence hepatic microcirculatory disturbance caused by HSCs construction. Second, we assessed gene expression in the liver only by microscopic examination in pre-preserved donor liver without time course in after reperfusion. However, DNRhoK expression inhibited the phosphorylation of the ERM family and that there is a positive correlation between the gene expression and Rho-kinase activity. Third, in the present study, the constitutive inhibition of NF-kb by DNRhoK might have inhibited a production of pro-inflammatory cytokines and time-dependent inflammatory response after reperfusion. However, we did not examine the direct relationship between Rhokinase and chemokines or adhesion molecules. Previous studies have shown that Rho-kinase mediates upregulation of pro-inflammatory molecules, including NAD(P)H, IL-6, monocyte chemoattractant protein (MCP-1), macrophage migration inhibitory factor (MIF) and interferon (IFN)-g. This point also remains to be examined in a future study.
In summary, the present study demonstrates the crucial role of Rho-kinase-mediated ROS production through the NADPH oxidase system in hepatocytes during the hyperacute period of reperfusion in vivo and the constitutive inhibition of Rho-kinase may prevent lethal liver injury caused by primary graft non-function. Although the focus here is the primary graft non-function, many studies show that Rho-kinase is also involved in the mechanisms of chronic graft rejection 36 or migration of cancer cells. 37 The ROS produced through Rho-kinase may involve in the generation of liver injury in fatty liver. Therefore, in the future, the targeted inhibition of Rho-kinase should provide a new avenue for gene therapy aimed at protecting organs at the various risks in the transplantation therapy.
Materials and methods

Animals
Inbred male Brown -Norway rats (Charles River Inc., Kanagawa, Japan, weighing 260-300 g) were used for both donors and recipients to avoid immunological influence. The present study was conducted in compliance with the Kyushu University Institutional Animal Care and Use committee.
Orthotopic rat liver transplantation
Orthotopic liver transplantation was performed by the cuff technique as described previously. 38 Briefly, under diethyl ether inhalation anesthesia, the liver of the donor was skeletonized and perfused in situ through the abdominal aorta with 20 ml of chilled lactated Ringer's solution. The liver was excised to a basin filled with UW solution (41C) perfused through the portal vein with 5 ml of chilled UW solution and stored at 41C. At the end of the storage period, the liver were flushed Rho-kinase in treatment of cold I/R-induced acute lethal liver injury S Shiotani et al in situ with 5 ml of chilled lactated Ringer's solution and transplanted into recipient animals with the cuff technique. The anhepatic time ranged from 12 to 16 min. The hepatic artery was not reconstructed because there is no difference in the liver function between reconstruction and non-reconstruction model immediately after reperfusion. 39 The bile duct connection was made with an intraluminal polyethylene splint. The cold preservation time was set to 24 h during all animal protocols.
Preparation of liposomes with entrapped Cl 2 MDP and animal protocol of Kupffer cell depletion Multilamellar liposomes were prepared as described previously. 40 Briefly, 86 mg of phosphatidylcholine and 8 mg of cholesterol, in the molar ratio 6:1 (Sigma Aldrich, Japan Co., Tokyo, Japan) were dissolved in 20 ml of methanol/chloroform (1:1) in a round-bottom flask. The thin film that formed on interior of the flask after lowvacuum rotary evaporation at 371C was dispersed in 10 ml of phosphate-buffered saline (PBS) (10 mM, pH 7.4), containing 2.5 g of dichloromethylene diphosphonate (Cl 2 MDP), by gentle rotation for 10 min. Free Cl 2 MDP was removed by rinsing the liposomes with PBS and centrifuging them for 30 min at 100 000 g at 161C. The liposomes were then resuspended in 4 ml PBS; 2 ml was intravenously (i.v.) injected per (rat) animal. Forty-eight hours before harvest, 2 ml liposomes with entrapped Cl 2 MDP were injected via the penile vein. 40 The control rats received vehicle injection. The liver treated with Cl 2 MDP and vehicle was harvested from the donor rat and transplanted into the recipient rat after preservation (41C) in UW solution for 24 h.
Measurement of superoxide production in liver tissue
Fifteen to thirty minutes after the reperfusion, 25 superoxide production by liver tissues was measured using lucigenin chemiluminescence method as described previously. 11, 21, 23, 41 Lucigenin luminescence is specific for superoxide and thus is useful for measurement of tissue superoxide production. 42 However, because of the recent criticism regarding the use of this assay as a method to detect superoxides, 43 we validated our findings with lucigenin, using the superoxide-specific scavenger, tiron. 21, 23, 24 Indeed, tiron abolished the lucigenin signal, confirming the validity of our method.
Scintillation vials with 1 ml 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid-buffered physiological salt solution containing 250 mmol/l lucigenin (bis-N-methylacridinium nitrate) were placed into a scintillation counter (Luminesence Reader BLR 301, Aloka, Japan) switched to the out-of-coincidence mode. After dark adaptation, background counts were recorded for 3 min and freshly isolated liver tissue was added to the vial. Scintillation counts were then recorded every 1 min for 15 min at 371C, and the background counts were subtracted. Then, to confirm the validity of superoxide production in this system, 20 mmol/l tiron, a superoxidespecific scavenger, was added to the solutions attenuating superoxide production every 1 min for 5 min in all experiments. The liver tissue was then dried by placing at room temperature for 24 h, for determination of dry weight. Lucigenin counts were expressed as counts per 10 min per mg dry weight. To evaluate the intracellular enzymatic sources responsible for the I/R-induced production of ROS, the measurement was also performed in the presence of the following drugs: (1) indomethacin (100 mM, cyclooxygenase inhibitor), 44 (2) rotenone (5 mM, mitochondrial complex I inhibitor) 45 and (3) 20 which are DNRhoK mutants driven by the cytomegalovirus promoter with a c-myc tag, were prepared through homologous recombination between co-transfected pJM17 and the shuttle plasmid in 293 cells. Integration of the transgene into the adenoviral genome was determined by a polymerase chain reaction and restriction analysis. The titer of the virus stock was assessed by plaque formation assay that used the 293 cells and was expressed as plaque-forming unit (pfu). Adenovirus vectors with b-galactosidase were used as a control. Three days before harvesting of the liver grafts, AdDNRhoK and AdLacZ (1 Â 10 9 and 6 Â 10
9
, respectively) were administrated i.v. via the penile vein in a volume of 2 ml. 47 In a pilot study, we examined the expression of the LacZ gene in the donor liver by X-gal staining 1, 3, 5 and 7 days after the gene transfer and confirmed that the highest expression of LacZ was observed 3 days after injection (data not shown).
Measurement of Rho-kinase activity
Fifteen minutes after reperfusion, 24 liver tissues were carefully isolated and total protein was extracted from each graft with sample buffer containing 0.5 M Tris-HCl (pH 6.8), 10% sodium dodecyl sulfate (SDS) (Sigma Aldrich Japan Co., Tokyo, Japan) and glycerol (Waco Pure Chemical Ind., Osaka, Japan). The protein content of the extraction was quantified using BCA protein assay system (Pierce, IL, USA), and was subjected to SDS-polyacrylamide gel electrophoresis immunoblot analysis. To evaluate Rho-kinase activity, the extent of phosphorylation of the ERM family, a substrate of Rho-kinase, was quantified by western blot analysis, using rabbit anti-human moesin polyclonal antibody (anti-phosphorylated Thr558), which also binds to phosphorylated ezrin (Thr567) and radixin (Thr 564), as described previously. 48 Goat anti-rabbit IgG labeled with horseradish peroxidase (Santa Cruz Biotechnology Inc., CA, USA) was used as a second antibody, and ECL plus assay system (Amersham Pharmacia Biotech, Buckinghamshire, UK) was used to detect the bands of target proteins.
Cytokine levels in liver tissue
Three hours after the reperfusion, 24 hepatic levels of tumor necrosis factor (TNF)-a and interleukin (IL)-1b were quantified using an enzyme-linked immunosorbent assay (ELISA) kit (Quantikine M TNF-a, IL-1b; R&D Systems, Minneapolis, MN, USA). The liver was perfused in situ with saline through the portal vein. The liver was then harvested and homogenized in extraction buffer (Tris 50 mmol/l, NaCl 150 mmol/l, Triton X-100
Rho-kinase in treatment of cold I/R-induced acute lethal liver injury S Shiotani et al 1%, and protease inhibitor cocktail) (Complete Mini; Roche, Basel, Switzerland). The homogenate was shaken on ice and then centrifuged at 3000 g and 41C for 15 min. TNF-a and IL-1b were quantified using a commercial ELISA kit according to the manufacturer's guidelines.
Histological studies
A liver specimen was fixed in 10% buffer formalin, embedded in paraffin and stained with hematoxylin and eosin. The elimination effect of Kupffer cells by Cl 2 MDP was judged by immunohistochemistry using anti-rat ED-1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). 39 For X-gal staining, liver specimen was embedded in OTC compound and was kept at À801C until staining. The frozen sections (8 mm) were fixed with glutaraldehyde, and stained with X-gal (5-bromo-4-chloro-indolyl-b-D-galactopyranoside) at 371C for 2 h. To distinguish the transfected cells, hematoxylin and eosin staining was performed on the specimen with Xgal stain.
Laser Doppler perfusion images (LDPIs)
Measurements of microcirculatory blood flow of the liver graft were made using a LDPI analyzer (Moor Instruments, Devon, UK). 49 LDPI, which is an easy, noninvasive and reliable blood-flow detection system, can only detect relatively superficial flow conditions; the laser only reaches 2-3 mm in depth from the liver surface, suggesting that LDPI might mainly reflect microcirculatory blood flow. LDF correlates well with invasive methods of measuring the surface hepatic microcirculation. 50 To minimize data variables due to anesthesia and temperature, the LDPI index was expressed as the ratio of the liver to the kidney blood flow. Accordingly, after two times of recording with the laser Doppler color images, the average perfusion of the liver was calculated on the basis of colored histogram pixels. Low or no blood perfusion was displayed as dark blue, whereas the highest perfusion interval was displayed as red to white. Perfusion analysis was performed sequentially (a) immediately after laparotomy (sham), (b) 30 min, (c) 3 h and (d) 12 h after reperfusion both in the control group with AdLacZ and in the treated group with AdDNRhoK.
Statistical analysis
Results are expressed as mean7s.e.m. Throughout the text, n represents the number of animals tested. A twoway analysis of variance (ANOVA) was performed to evaluate the global statistical significance, and if a significant F-value was found, Bonferroni's post hoc test was performed to identify the difference among the groups. Differences in a single parameter among groups were compared by using a one-way ANOVA followed by a Bonferroni's test for multiple comparisons. A P-value of o0.05 was considered to be statistically significant.
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